GPT and Hypoglycemia: Other objectives include assessing the possible effect of weekly 1.5 mg dulaglutide on different parameters, such as blood pressure, lipid profile, aspartate-aminotransferase (AST), alanine-aminotransferase (ALT), alkaline phosphatase (ALP), serum creatinine, and estimated glomerular filtration rate (eGFR) levels after 6 and 12 months from the baseline, and exploring the most common dulaglutide side effects reported by T2DM patients, such as nausea, vomiting, diarrhea, abdominal pain, dyspepsia, local injection reaction, and hypoglycemia.